HAVCR2 and hepatocellular carcinoma: There are vigorous ongoing efforts in CAR-T cell therapy and targeting other checkpoint molecules such as TIM-3, LAG-3, and TIGIT, which might broaden the range of ICI-based treatments for HCC.